Ionis Pharmaceuticals Inc.
IONS
NGS
Sector: Healthcare
Industry: Biotechnology
45.70
USD
2.41
(5.57%)
Optionable: Yes Market Cap: 5,272 M 90-day average vol: 997,487
Previous close: 43.29 Open: 43.0 Bid: 45.99 Ask: 45.99
52 week range
25.04 45.95
Last updated: Monday 8th August 2022
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
Are you?
Metrics
Valuation
Price per Sales TTM ($) | 7.37 |
Price per Book TTM ($) | 7.49 |
PE Ratio (TTM) | -3,749.00 |
Book Value per Share ($) | 3.76 |
5 Year PE Range | -152.1 , 1023.1 |
Returns
7 Day Return | 21.90% | |
1 Month Return | 23.01% | |
3 Month Return | 44.12% | |
1 Year Return | 18.52% | |
3 Year Return | -33.09% | |
5 Year Return | -5.40% | |
YTD Return | 50.18% |
Risk
Analyst Estimates
Financial Health
Technicals
RSI (14 Day) | 75.02 |
14 Day SMA ($) | 39.40 |
14 Day EMA ($) | 39.93 |
Money Flow Index | 40.10 |
Average True Range | 1.81 |
50 Day SMA ($) | 37.39 |
200 Day SMA ($) | 34.57 |
ADX | 26.81 |
MACD | 1.23 |
Growth
Free Cash Flow QoQ Growth | -117.62% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | -128.93% |
Revenue QoQ Growth | -67.75% |
EPS YoY Growth | 0.00% |
Profitability
Chart
News
Ionis to present at the Cowen Annual Health Care Conference
Yahoo Finance 3/1/2022
Analysts Are More Bearish On Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Than They Used To Be
Yahoo Finance 2/25/2022
Ionis (IONS) Q4 Earnings & Revenues Beat Estimates, Stock Up
Yahoo Finance 2/25/2022
Company News for Feb 25, 2022
Yahoo Finance 2/25/2022
Ionis Pharmaceuticals, Inc. (IONS) CEO Brett Monia on Q4 2021 Results - Earnings Call Transcript
Seeking Alpha 2/24/2022
Ionis Pharmaceuticals (IONS) Q4 Earnings and Revenues Beat Estimates
Yahoo Finance 2/24/2022
Ionis PharmaceuticalsEPS of $1.41, revenue of $440M beats by $155.92M
Seeking Alpha 2/24/2022
Ionis reports fourth quarter and full year 2021 financial results and recent business achievements
Yahoo Finance 2/24/2022
Ionis Pharmaceuticals Q4 2021 Earnings Preview
Seeking Alpha 2/23/2022
Ionis Pharmaceuticals (IONS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Yahoo Finance 2/17/2022
2 Unstoppable Growth-Oriented ETFs To Hold for the Long Haul
Yahoo Finance 2/17/2022
Ionis to hold full year 2021 financial results webcast
Yahoo Finance 2/10/2022
Grandfield & Dodd, Llc Buys AutoZone Inc, Teledyne Technologies Inc, IAC/InterActiveCorp, ...
Yahoo Finance 2/8/2022
Ionis Pharmaceuticals (NASDAQ:IONS) shareholders have endured a 48% loss from investing in the stock a year ago
Yahoo Finance 2/7/2022
Ionis Pharma suffers double downgrade at BofA on lack of notable catalysts
Seeking Alpha 2/1/2022
Pfizer (PFE) Ends Vupanorsen Development, Returns Rights to Ionis
Yahoo Finance 2/1/2022
Pfizer Backs Out Of Deal, But Former Partner Ionis Pares Its Losses
Yahoo Finance 1/31/2022
Trend Analysis & Forecast
Read more on this trend analysis & forecast here - uptrenddowntrend.com
Trendlast: 17.324
Financials
IONS Income Statement
Annual
| Dec-12 | Dec-13 | Dec-14 | Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 102 M | 147 M | 214 M | 284 M | 373 M | 514 M | 600 M | 1,123 M | 729 M | 810 M |
| Cost of sales | 144 M | 169 M | 225 M | 304 M | -16 M | -15 M | -10 M | -4 M | -17 M | -26 M |
| Gross operating profit | -56 M | -37 M | -28 M | -39 M | 373 M | 514 M | 598 M | 1,118 M | 717 M | 800 M |
| Selling Gen & administrative expense | 13 M | 15 M | 20 M | 37 M | 49 M | 108 M | 245 M | 287 M | 332 M | 171 M |
| Research & development expense | 158 M | 184 M | 242 M | 322 M | 344 M | 375 M | 415 M | 466 M | 535 M | 643 M |
| Operating income | -69 M | -52 M | -48 M | -76 M | -20 M | 31 M | -61 M | 366 M | -150 M | -15 M |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income net | 15 M | 4 M | 16 M | 25 M | 1 M | -3 M | 30 M | 30 M | 25 M | -5 M |
| Pre-tax Income (EBT) | -75 M | -67 M | -54 M | -88 M | -57 M | -17 M | -76 M | 347 M | -135 M | -29 M |
| Income taxes | -9 M | -6 M | -15 M | 372000 | 3 M | -6 M | -291 M | 44 M | 345 M | -551000 |
| Net income from total operations | -65 M | -61 M | -39 M | -88 M | -60 M | -11 M | 215 M | 303 M | -480 M | -29 M |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total net income | -65 M | -61 M | -39 M | -88 M | -60 M | 346000 | 274 M | 294 M | -444 M | -29 M |
| Preferred dividends | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net income available for common | -65 M | -61 M | -39 M | -88 M | -60 M | -11 M | 215 M | 303 M | -480 M | -29 M |
| Depreciation | 15 M | 15 M | 17 M | 18 M | 16 M | 15 M | 12 M | 9 M | 29 M | 37 M |
| Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income before depreciation (EBITDA) | -43 M | -37 M | -23 M | -41 M | -10 M | 36 M | -19 M | 412 M | -111 M | -5 M |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic EPS total | -0.65 | -0.55 | -0.33 | -0.74 | -0.72 | 0.15 | 2.09 | 2.12 | -3.23 | -0.2 |
| Diluted EPS total | -0.65 | -0.55 | -0.33 | -0.74 | -0.72 | 0.15 | 2.07 | 2.08 | -3.23 | -0.2 |
Top MarketXLS Rank stocks
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started today
Stand with Ukraine
As the situation in Ukraine escalates, many of us in MarketXLS are left with emotions too overwhelming to name. If you’d like to show your support, but aren’t sure how to, we want to help make it easier for you to act.
For any amount donated, we’ll extend your MarketXLS subscription for double of the donated amount. Please send proof of your payment to support@marketxls.com to avail the extention
From all of us at MarketXLS, thank you!